

# Polyneuropathies- all types

Charles E. Argoff, M.D.

Professor of Neurology

Albany Medical College

Director, Comprehensive Pain Center

Director, Pain Management Fellowship

Albany Medical Center

# Goals and Objectives

- Understand the approach to the evaluation of the patient with polyneuropathy
- Recognize the signs and symptoms associated with nerve disorders
- Know the basic pathological processes affecting peripheral nerves
- Understand how nerve disorders are classified and the common etiologies for nerve disease
- Be able to identify patients with small fiber polyneuropathy

# Background

- Peripheral neuropathy is experienced by approximately 40 million people in the US
- Many peripheral neuropathies are mixed neuropathies with both large fiber and small fiber involvement
- Increasingly recognized is the demonstration of specific involvement of small myelinated or unmyelinated fibers, e.g. small fiber neuropathies

# Approach to Diagnosis in Nerve Disorders

- History
- Physical Examination
- Family History
  
- Investigations (not all are needed)
  - Bloodwork: severity/progress of neuropathy guides work-up. Especially to look for treatable causes of neuropathy
  - Electrodiagnostic: EMG/NCS; axonal versus demyelinating
    - Large (not small) fiber neuropathies
  - Lumbar puncture
  - Nerve biopsy
  - Genetic testing (for certain inherited neuropathies)

\*Often, no cause is determined (idiopathic)\*

# Evaluating Nerve Disorders

## Symptoms

- Negative
  - Weakness
  - Numbness
  - Unsteadiness
- Positive
  - Paresthesias, dysesthesias
  - Hyperpathia, allodynia
  - Restless legs

## Examination

- Negative
  - Weakness\*, clumsiness
  - Atrophy
  - Sensory loss\*
    - Light touch, pinprick, temperature, vibration, joint position are tested
  - Diminished or absent reflexes\*
- Positive
  - Fasciculations
  - Cramps

\*In the distribution of the abnormal nerve(s)

# Classification of Nerve Disorders

- **Tempo & Course**

- Acute
- Subacute
- Chronic
- Monophasic
- Relapsing
- Progressive

- **Nerve type**

- Motor
- Sensory
- Autonomic
- Mixed

- **Distribution**


- Mononeuropathy
- Mononeuropathy multiplex
- Polyneuropathy
- Radiculopathy
- Polyradiculoneuropathy
- Plexopathy

- **Pathology**

- **Etiology**

# Pathologic Processes

- Wallerian degeneration (anterograde)
- “Dying-back” axonal degeneration
- Segmental demyelination
- Neuronopathy



# Nerve Injury

- Neurapraxia
  - Focal demyelination
  - Anoxia/ischemia, mechanical factors
- Axonotmesis-loss of axon continuity
- Neurotmesis –connective tissue involved
  - I: perineurium, nerve sheath preserved
  - II:nerve sheath preserved only
  - III: complete separation of nerve



# Etiology of Nerve Disorders


- Vascular
  - Systemic necrotizing vasculitis
  - Wegener granulomatosis
  - Giant cell arteritis
  - Rheumatoid arthritis
  - Systemic lupus erythematosus
  - Sjogren syndrome
  - Scleroderma
  - Mixed connective tissue disease
- Infectious/granulomatous
  - AIDS
  - Leprosy
  - Diphtheria
  - Sarcoidosis
  - Sepsis/multiorgan failure
  - Lyme disease
  - Herpes Zoster
  - Poliomyelitis
- Inflammatory
  - AIDP
  - CIDP
- Neoplastic
  - Compression/infiltration by tumor
  - Paraneoplastic syndromes
  - Paraproteinemias
  - Amyloidosis
- Toxic
  - Alcohol
  - Therapeutic drugs (extensive list; includes antibiotics (INH), AED's (phenytoin), platinum-containing chemotherapies)
  - Hexacarbons, organophosphates
  - Paralytic shellfish poisoning
  - Heavy metals
- Metabolic
  - Diabetes/other endocrinopathies
  - Uremia
  - Liver disease
  - Vitamin B12 deficiency
- Heredodegenerative
  - HMSN/HSAN
  - Familial amyloidosis
  - Friedreich Ataxia
  - HNPP
  - Porphyria
  - Metachromatic leukodystrophy
  - Krabbe disease
  - Abetalipoproteinemia
  - Tangier disease
  - Refsum disease
  - Fabry disease
- Entrapment

# Mononeuropathies

- Isolated nerve lesions with deficits restricted to the nerve in question
- Commonly related to entrapment, trauma
- Frequently encountered mononeuropathies in clinical practice include:
  - Median
  - Ulnar
  - Radial
  - Peroneal
  - Lateral femoral cutaneous



# Entrapment Neuropathy

- Nerves at risk pass through tight fibrous or fibro-osseous channels
- Mechanical distortion leads to focal demyelination and possibly axonal injury
- Most Common: Median nerve at wrist (carpal tunnel), Ulnar nerve at elbow, peroneal nerve at fibular head



**MEDIAN**


**LATERAL FEMORAL CUTANEOUS**



**Fibular (Peroneal)**



**ULNAR**



**RADIAL**

# Mononeuropathy Multiplex

- Several individual nerves are affected
  - Usually at random and non-contiguously
- Examination reveals deficits attributable to the involvement of one or more isolated peripheral nerves
- Often related to vasculitis or other inflammatory/autoimmune conditions.
- Diabetes

# Polyneuropathies

- Refers to a disorder of numerous peripheral nerves at a given time
- Often characterized by a distal, symmetric sensory deficit (“glove and stocking” distribution)
- Can be further subclassified as primarily axonal or demyelinating in nature


# Polyneuropathies

## common considerations by pathology

- Axonal
  - Metabolic
  - Inherited
  - Nutritional, toxins
  - Vasculitis
- Demyelinating
  - Immune mediated/inflammatory
  - Inherited
  - nutritional, toxins

# Axonal Polyneuropathies

- **Diabetic Neuropathy**
  - Most often a distal symmetric polyneuropathy
    - Large or small fiber; autonomic neuropathy may coexist
  - Asymmetric neuropathy may involve cranial nerves, thoracic or limb nerves
    - Result from ischemia (vasa nervosa); entrapments
  - Proximal motor neuropathy (diabetic amyotrophy) with severe proximal limb pain and weakness
    - Believed to result from immune-mediated epineural microvasculitis





# Axonal Polyneuropathy

## Select other causes

- Renal Failure
- Alcohol
  - Probably multifactorial
  - Nutrition important
  - Painful sensory/”Stocking-glove” type
- Nutritional- eg vitamin B12
- Inherited neuropathies (eg CMT type 2)

# Toxic Neuropathies

may be axonal or demyelinating

- Arsenic
- Heavy Metals (lead, mercury)
- Antibiotics (eg INH)
- Chemotherapy (eg taxol, cis-platinum)
- Thallium
- Hexacarbons
- Seizure Medicines (Phenytoin)
- Many More.....the list is long!

# Demyelinating Polyneuropathies

- **Charcot-Marie-Tooth hereditary motor and sensory neuropathy, type 1 (CMT-1)**
  - Most common demyelinating polyneuropathy
  - Distal weakness and atrophy
  - Musculoskeletal deformities (pes cavus, hammer toes, “inverted champagne bottle” legs)
  - Sensory symptoms less common
  - EMG/NCS useful in determining demyelinating from axonal variants
  - Genetic testing available
  - Type 2 CMT/HMSN is axonal but similar phenotype



# Hereditary (HMSN)- classification

- HMSN1- autosomal dominant/demyelinating
  - Types 1A-1D
- HNPP
- HMSN 2-autosomal Dominant/axonal
  - 2A-2F
- HMSN3 (Dejerine sottas)
- HMSN 4 (A-F)
  - Recessive (both axonal and demyelinating)
- HMSN X

# Demyelinating Polyneuropathies

- **Acute Inflammatory Polyradiculoneuropathy (AIDP; Guillain-Barre syndrome)**
  - Most common **acquired** demyelinating polyneuropathy
  - Autoimmune segmental demyelination of motor > sensory nerves
  - Molecular mimicry (i.e. Campylobacter jejuni)
  - Ascending weakness and respiratory compromise occurring over days-weeks
  - Areflexia
  - Facial weakness common
  - Autonomic dysfunction common
  - Usually monophasic; complete recovery is possible
  - CSF finding: albumino-cytologic dissociation (elevated protein with normal or low white blood cell count)
  - EMG/NCS useful in diagnosis (variants, mimics)
  - Acute treatment: IVIG, plasmapheresis


# Infectious

- Leprosy
  - Common worldwide in past, still to be considered
- Diphtheria
  - Oculobulbar involvement
- Lyme Disease
- Herpes Zoster
- HIV
- Poliomyelitis, other enteroviruses, West Nile

# Neuropathy with myelopathy

- **Friedreich's ataxia**

- Most common autosomal recessive ataxia
- Results from an expanded GAA trinucleotide repeat in a noncoding region of the gene for frataxin on chromosome 9 (loss of function)
- Signs include progressive limb and gait ataxia, dysarthria, loss of joint position and vibration senses, absent deep tendon reflexes in legs, extensor plantar responses
- Usually presents by 8-15 years; loss of ambulation by 15 years after onset; >95% wheelchair bound by age 45
- Associated features include kyphoscoliosis with restrictive lung disease, cardiomyopathy with arrhythmias and heart failure, optic atrophy, and diabetes mellitus
- Characterized degeneration of dorsal root ganglia and axons, beginning in the periphery, with ultimate loss of neurons and secondary gliosis. Degeneration of corticospinal tracts, dorsal columns, spinocerebellar tracts.



cerebellar ataxia

# Amyotrophic Lateral Sclerosis (ALS)



- Disorder of upper and lower motor nerves
- Usually death 2-6 years after diagnosis
- Lower motor nerve – atrophy, weakness, fasciculations
- Upper motor nerve- “long tract signs”- brisk deep tendon reflexes, pathologic reflexes (eg Babinski)



# ALS

- 2 most common forms of presentation- limb onset & bulbar onset
- Widespread denervation of muscle in body
- Affects motor nerves (minimal sensory involvement)
- Respiratory failure
- Dysphagia
- Loss of independence, may become non-ambulatory

# What is Neuropathic Pain?


- Pain arising as a direct consequence of diseases affecting the somatosensory system.

Grading system: definite, probable, possible

R-D Treede et al. *Neurology* 2008, Proposed by IASP Neuropathic Pain Special Interest Group.

- In Plain English: Pain from the nerves, spinal cord, or brain. Not originating in the bones, muscles, organs.

# Which person has pain?



# Differential diagnosis- Widespread or Difficult to Diagnose Localized Pain

## ■ Rheumatic

- Arthritis (OA, RA)
- Polymyalgia Rheumatica
- Osteomalacia
- Myopathy
- Spondyloarthropathies
- Systemic Lupus Erythematosus

## ■ Endocrine

- Hypothyroidism
- Diabetes

## ■ Neurologic

- Multiple sclerosis
- Chiari malformation
- Spinal stenosis
- Radiculopathy
- Polyuropathy
- Fibromyalgia

## ■ Other

- SMALL FIBER POLYNEUROPATHY?

# Common Neuropathic Pain Diagnoses

- Diabetic Peripheral Neuropathy\*
- Post Herpetic Neuralgia\*
- Radicular Pain (neuropathic low back pain)
- Traumatic Peripheral Nerve Injury
- Complex Regional Pain Syndrome
- Chronic Postop Pain
- Phantom Limb Pain
- HIV related neuropathy
- Spinal Cord Injury\*
- Post-stroke pain
- Trigeminal Neuralgia\*
- Small Fiber Polyneuropathy

\* FDA approved medications available

# Polyneuropathies may involve small and large nerve fibers

	<b>Large-fiber neuropathy</b>	<b>Small-fiber neuropathy</b>
<b>Symptoms</b>	Numbness, pins and needles, tingling, poor balance	Pain: burning, electric shocks, stabbing pain, numbness
<b>Exam Findings</b>	Reflexes, proprioception Vibration, +/- motor	Thermal, pin-prick sensation, allodynia
<b>Functional changes</b>	Pressure, balance, fall risk	Nociception; protective sensation
<b>Diagnostic test</b>	EMG/NCV, sural nerve biopsy	QST, nerve biopsy, Intraepidermal nerve fiber density (skin biopsy)

# Small Fiber Polyneuropathy Definition and Key Facts

- Small fiber neuropathies (SFN) result from damage to the peripheral nerves affecting small myelinated A-Delta and unmyelinated C fibers.
- The fibers affected include both small somatic as well as autonomic fibers
- Thermal perception and nociception are subserved by small fibers
- Enteric function is also subserved by small fibers
- LARGE fibers are heavily myelinated and involved in muscle control, as well as touch, vibration and position sense

# Small Fiber Polyneuropathy Definition and Key Facts-2

- Most SFNs occur in a length-dependent fashion – first stocking distribution changes and then later glove distribution
- Less common but no longer rare, non-length dependent SFN can result in symptoms involving the face, trunk, proximal limbs, or other more localized areas
- The pathogenesis of injury to small fibers is not well understood



# Small Fiber Polyneuropathy Definition and Key Facts-3

- SFN can progress to involve large fibers as well
- Muscle cramps may be one of the presenting complaints of SFN
- Epidemiologic data from the Netherlands suggest a minimum incidence of 12/100,000 people
- Children also can experience SFN- the diagnosis may be more challenging in adults as will be discussed later

Hovaguimian A, Gibbons CH. Diagnosis and Treatment of Pain in Small-fiber Neuropathy *Curr Pain Headache Rep* (2011) 15:193-200; Peters MJ, et al. Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. *Neurology* 2013;81:1356-60; Oaklander AL, Klein MM. Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. *Pediatrics* 2013;131:e1091-1100.)

# Small Fiber Polyneuropathy: BIG impact on quality of life

- In one study that measured the impact specifically on SFPN on quality of life, 265 patients enrolled
- SFN-SIQ, VAS, 36 item short form health survey evaluated
- SFPN patients demonstrated a marked overall reduction in quality of life
- Physical and mental measures were decreased
- Other reported data suggests significant direct and indirect healthcare costs with increasing levels of pain in idiopathic SFN

# Disorders Associated with SFN

- Diabetes
- Impaired Glucose Tolerance
- Metabolic Syndrome
- Sarcoidosis
- Thyroid Dysfunction
- HIV
- Vitamin B<sub>12</sub> Deficiency
- Vitamin B<sub>1</sub> Deficiency
- Chemotherapy drugs
- Antiviral Agents
- Celiac Disease
- Sjogren's Syndrome
- Paraneoplastic Syndromes
- Paraproteinemia
- Rheumatoid Arthritis
- Idiopathic (up to 50%!)

# Disorders Associated with SFN-2

- Guillain-Barre Syndrome
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Restless Leg Syndrome
- Hepatitis C
- Systemic Lupus Erythematosus
- Amyloidosis
- Fabry's Disease
- Ehlers Danlos Syndrome
- Hereditary Sensory Neuropathies
- Hereditary Autonomic Neuropathies
- Central post stroke pain

## Disorders associated with SFN-3

- Alcohol use
- Rabies, varicella or Lyme vaccine
- Anti-TNF inhibitors
- Metonidazole
- Linezolid
- Statins
- Sodium channelopathies
- Parkinson disease
- Pompe disease
- Wilson disease
- ALS
- Fragile X
- X linked adrenoleukodystrophy
- Chronic renal disease

# SFN Pathophysiology- Possible role of Sodium Channel mutations

- Genetic variants in the structure/function of sodium channels may lead to either loss of pain sensitivity or enhanced pain
- Inactivating mutations in SCN9A, which encodes Nav 1.7 is associated with congenital insensitivity to pain
- Gain of function mutations in SCN9A may result in SFN
- Various mutations in TRPA 1 or Nav1.8(SCN10A) and Nav 1.9 (SCN11A) also may lead to SFN
- Might this information lead to new treatments?

# SFN Symptoms

- Symptoms vary widely in severity
- Often affected individuals describe a gradual onset of vague distal sensory disturbances
- Examples include feeling like there is sand in the person's shoe, a sock feeling as if it has pebbles in it, pins and needle sensations, cold painful sensations or tingling.

# SFN Symptoms-2

- Burning pain in the extremities, sometimes severe
- Allodynia and hyperesthesia
- Socks or bedsheets may be painful
- Symptoms are often worse at night



# SFN Symptoms-3

- Autonomic and enteric dysfunction including: dry eyes, dry mouth, lightheadedness with changes in posture, syncope, abnormalities of sweating, erectile dysfunction, GI symptoms such as nausea and emesis, constipation, diarrhea, changes in urinary frequency including nocturia.

# SFN- Diagnosis

- Normal or practically normal basic physical and neurological examination!!!
- However, possible findings include decreased pin prick, diminished thermal sensation, hyperalgesia, dry skin
- A detailed history is vital to making the diagnosis
- Ancillary testing may be helpful as well

# Common Diagnostic Studies and Limitations

## Studies

- Blood studies
- X-ray, CT, MRI
- Electromyography (EMG)
- Nerve conduction velocity (NCV)
- ***Quantitative sensory testing (QST)***
- ***Skin biopsy***

## Limitations of EMG/NCV

- Insensitive in acute injury
- Normal result does not rule out neuropathic pain
- Cannot assess function of small-fiber nerves involved in most neuropathic pain

# SFN-Diagnosis-additional information

- Various written tools such as the Neuropathic Pain Symptom Inventory may be helpful
- Quantitative Sensory Testing- this can detect thresholds of thermal pain, thermal sensation and vibration for example. Contact Heat Evoked Potentials attempts to link peripheral activation to central.
- Quantitative Sudomotor Axon Reflex testing (QSART)

# SFN-Diagnosis-Skin Biopsy

- Skin Biopsy- this has become widely accepted as a technique to evaluate the structure of small nerve fibers.
- The standard is a 3-mm skin punch biopsy that can be taken from anywhere over the body.
- Due to the need to compare to normal values the lower extremity is most commonly assessed (also length dependent SFN more common than non-length dependent)
- The results are expressed as the number of intraepidermal fibers per mm
- The sensitivity (78-92%) and specificity (65-90%) is fairly high for this technique

# SFN-Skin Biopsy- 2

- Intraepidermal nerve fibers (IENF) are unmyelinated sensory endings that arise from the sub-papillary dermis
- They widely express the TRPV<sub>1</sub> receptor- this means they are distal nociceptors
- One of the more common areas to perform a skin biopsy for diagnostic purposes is 10cm proximal from the lateral malleolus
- Using antibodies against the protein gene product (PGP 9.5), a cytoplasmic ubiquitin carboxyl-terminal hydrolase, the number of fibers crossing the dermal-epidermal junction can be quantified – measured as IENF/millimeter

# SFN-Skin Biopsy- 3

- Studies have demonstrated stability of IENFD in normal controls as well as in patients with idiopathic SFN when re-biopsied in the same sensory territory after 3 weeks
- IEFND decreases with age in SNF associated with various etiologies
- IEFND has been found to be decreased in non-painful disorders such as Parkinson's disease, ALS, critical illness and peripheral arterial disease- more to be discussed!



# Loss of skin nerve fibers in PHN

## PGP 9.5 Immunolabeling of Sensory Nerve Endings in Skin Biopsies

### Subject without PHN pain

Contralateral site


Shingles site




### Subject with PHN pain

Contralateral site

Shingles site



The density of epidermal nerve endings in previously shingles-affected skin



A.L. Oaklander et al., 1998

Oaklander AL, et al *Ann Neurol* 1998;  
Oaklander AL, et al *Pain* 2001





# SFN- Diagnosis-Corneal Confocal Microscopy (CCM)

- CCM visualizes the C-fibers originating from the trigeminal nerve that travel to the Bowman's membrane of the cornea
- CCM software can quantify: corneal nerve fiber density (CNFD), corneal nerve fiber tortuosity, corneal nerve branch density, corneal nerve fiber length
- Studies support that patients with both non-length dependent as well as length dependent SFN demonstrate a decrease in CNFD

# Functional and Imaging Assessment of Small Nerves

- Quantitative Sensory Testing
- Microneurography
- Nociceptive Evoked Potentials
- Peripheral Nerve Ultrasound
- Magnetic Resonance Imaging

## Small fiber polyneuropathy- blood/other tests

- Metabolic: thyroid functions, HbA<sub>1</sub>C, FBS
- Nutritional: CBC, Hepatic Profile, Vitamin B<sub>1</sub> and B<sub>12</sub>
- Infectious: CRP, HIV, Lyme, HBV, HCV
- Autoimmune: ESR, ANA, Anti-ENA, ANCA, anti-gliadin, RF, serum ACE, ? CXR
- Paraneoplastic: Tumor markers, LDH, Myeloma screen, SPE, anti-Hu and anti-CV<sub>2</sub>/CRMP-5 ab

## Small fiber polyneuropathy- blood/other tests(continued)

- Neurotoxins: urine and blood toxicology, review drug history
- Hereditary: alpha-galactosidase A, globotriaosylceramide levels, renal panel, urine protein, genetic testing for SCNgA or SCN10A
- Lumbar puncture: if you suspect inflammatory, auto-immune or paraneoplastic etiologies


# More about voltage gated sodium channelopathies

- $Na_v1.7$  and  $Na_v1.8$  gain of function mutations in inherited erythromelagia
- $Na_v1.7$  in paroxysmal extreme pain disorder- paroxysmal rectal, ocular or submandibular pain with flushing with possible autonomic dysfunction- 10 gain of function mutations have been identified
- $Na_v1.7$ ,  $Na_v1.8$  and  $Na_v1.9$  gain of function mutations in SFN



*“Discouraging Data on the Antidepressant (AS WELL AS MANY OTHER TREATMENTS)”*

# Gabapentin in the treatment of painful diabetic neuropathy\*



\*Not approved by FDA for this use

†  $P < 0.01$ ; ‡  $P < 0.05$

Adapted from Backonja M, et al. *JAMA*. 1998;280(21):1831-1836.

# SFN- Treatment

- Treat the treatable! If an underlying cause of SFN can be determined, optimal treatment of the causative condition may lessen the symptoms of SFN
- Few studies and no guidelines have examined the pharmacologic treatment of the pain associated with SFN
- In one such study, both gabapentin and tramadol were found to be effective for SFN



# Neuropathic pain recommendations of various societies

	EFNS, Europe Neurology	Canadian Pain Society	IASP NeuPSIG
<b>First line</b>	TCA GBP/PGB Lidocaine 5% plaster	TCA GBP/PGB	TCA, SNRI GBP/PGB Lidocaine 5% Opioid (specific circumstances)
<b>Second line</b>	SNRI (Opioid)	SNRI Lidocaine 5%	Opioid Tramadol
<b>Third line</b>	Opioid Lamotrigine Capsaicin	Opioid (except methadone)	Paroxetine Bupropion NMDA antagonist
<b>Fourth line</b>		Methadone	

EFNS, European Federation of Neurological Societies; IASP, International Association for the Study of Pain; NeuPSIG, Neuropathic Pain Special Interest Group.  
Attaini N, et al. *Eur J Neurol*. 2006;15(11):1153-1169. Dworkin RH, et al. *Pain*. 2007;132(3):237-251.

Moulin DE, et al. *Pain Res Manag*. 2007;12(1):13-21.

## SFN- Is IVIG (intravenous immunoglobulin) an Emerging Treatment?

- A recent report described 3 patients with sarcoidosis and SFN who were experiencing severe pain as well as dysautonomia
- Each patient had biopsy proven SFN
- Each patient had failed to response to “conventional” analgesic/symptomatic approaches
- Each patient received an initial dose of IVIG 2g/kg followed by 1g/kg doses at regular intervals- each with dramatic resolution of pain and autonomic symptoms
- Further larger studies are warranted

## SFN- Is IVIG (intravenous immunoglobulin) an Emerging Treatment?-2

- Limited data for Sjogren's syndrome- IVIG 2g/kg
- Juvenile onset unexplained widespread pain treated with IVIG in 15 patients by Oaklander et al- treated at 2g/kg/month at least 3 times- 62% demonstrated significant improvement
- In another study, 46 patients with SFPN associated with dysautonomia were treated with one or more IVIG treatment- for patients with pain intensity levels  $\geq 3$  or with significant dysautonomia, the treatment was helpful

## SFN- Is IVIG (intravenous immunoglobulin) an Emerging Treatment?-3

- 55 patients with “apparently autoimmune” small-fiber polyneuropathy treated with IVIG
- IVIG treatment duration averaged 28 +/- 25 months
- Improvements were noted in autonomic function testing, pain reduction, sweat production
- 16% of patients were considered in remission after multiple treatments

# SFPN and Fibromyalgia

- Approximately 50% of patients who have been diagnosed with Fibromyalgia in several published studies have demonstrated findings consistent with SFPN on diagnostic biopsies- studies to be reviewed on subsequent slides
- What does that mean?
- What does that mean about interpreting FM studies that have already been published?

# CWP, SFPN and Fibromyalgia I

- 27 patients with fibromyalgia who satisfied the 2010 ACR criteria were compared to 30 matched controls
- 41% of skin biopsies from fibromyalgia subjects compared to 3% from controls were diagnostic for SFPN
- The Michigan Neuropathy Screening Instrument and Utah Early Neuropathy Scale scores were higher in fibromyalgia patients

# CWP, SFPN and Fibromyalgia II

- 25 patients with fibromyalgia were compared to 10 depressed patients and controls
- Small fiber evaluation included QST, pain-related evoked potentials and quantified intraepidermal nerve fiber density and regenerating IENF of the lower leg and upper thigh
- Compared with control subjects fibromyalgia patients BUT not depressed patients had impaired small fiber function

# CWP, SFPN and Fibromyalgia II (continued)


- Skin biopsy findings demonstrated that total and regenerating IENFs at the lower leg and upper thigh were reduced in patients with fibromyalgia compared with controls
- A reduction in unmyelinated nerve fiber bundles was seen in patients with fibromyalgia compared with depressed and control subjects
- The authors concluded that the results point towards a neuropathic nature of fibromyalgia.



# Complex chronic pelvic pain and SFN

- Retrospective study with objective to demonstrate the prevalence of SFN in patients with refractory chronic pelvic pain
- 25/39 patients (64%) demonstrated skin biopsy findings consistent with SFN
- Co-morbid conditions noted included GERD (46%), migraine (38%), IBS (33%), fibromyalgia (38%), endometriosis (15%), interstitial cystitis (18%), vulvodynia (5%), other chronic pain syndromes (36%)

# Patient Education



Levine T, et al. Small Nerves Big Problems: A comprehensive guide to small fiber neuropathy. Hilton Press. Chicago, IL (2017)

# Summary

- There are many (!) types of polyneuropathy
- Treatment varies depending upon the type
- Multiple medical conditions are associated with SFN including many considered common
- Recognizing SFN and its existence in perhaps more conditions than previously recognized may lead to improved treatment approaches